

PE-01ABT90-P

EBV/88; BZLF-1 (190-197) Peptide Powder

8-mer peptide based on EBV/88; BZLF-1



KINEXUS

Address: 8755 Ash Street, Suite 1
Vancouver, British Columbia,
Canada V6P 6T3

Email: info@kinexus.ca
Phone: 604-323-2547

Target Protein

Name Long:	Epstein-Barr Virus immediate-early lytic cycle protein
Name Alias:	CEF15
Species Origin:	Epstein-Barr virus

Peptide Structure

Peptide Name:	EBV/88; BZLF-1 (190-197)
Peptide Origin:	Based on amino acid residues 190-197 in the HLA-B8-restricted epitope from Epstein-Barr Virus immediate-early lytic cycle protein BZLF-1.
Peptide Sequence Location:	R190-L197
Peptide Sequence:	RAKFKQLL
Peptide N-Terminus:	Free amino
Peptide C-Terminus:	Acid
Peptide Modifications Other:	None

Production

Peptide Production Method:	Solid-phase peptide synthesis
Calculated Peptide Mass:	1002.2
% Peptide Purity:	> 90
Peptide Appearance:	White powder
Peptide Form:	Solid
Peptide Solubility:	Dissolve in 50 µl DMSO and dilute to desired concentration with water or aqueous buffer
Lot Number:	#28323 / SP01ABR
Amount:	1 mg
Storage Conditions:	Frozen at -20 °C
Storage Stability:	Over 1 year at -20 °C

This product is for in vitro research use only and is not intended for use in humans or animals.

For more information on our products please visit www.kinexusproducts.ca or contact us at 1-866-KINASES (546-2737)